ADMA Biologics
ADMA
105 hedge funds and large institutions have $190M invested in ADMA Biologics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 9 closing their positions.
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
114% more call options, than puts
Call options by funds: $817K | Put options by funds: $382K
77% more capital inflows, than outflows
Capital inflows: $27.7M | Capital outflows: $15.7M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 23
19% more funds holding
Funds holding: 88 → 105 (+17)
3.89% more ownership
Funds ownership: 49.65% → 53.54% (+3.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.98M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.59M |
| 3 |
Boothbay Fund Management
New York
|
+$3.31M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.83M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$4.71M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.34M |
| 3 |
CC
Clearline Capital
New York
|
-$1.89M |
| 4 |
Magnetar Financial
Evanston,
Illinois
|
-$977K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$672K |
ADMA Hedge Fund Activity: Q1 2022 in Review
105 of the 6,362 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2022, worth a combined $190M — up 39% from $137M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ADMA positions and 9 closed out — a net gain of 17 holders — while 33 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.98M. The largest seller was Nuveen, cutting an estimated $4.71M.
- 105 institutional investors held ADMA Biologics (ADMA) as of Q1 2022, up from 88 in Q4 2021.
- Funds reported $190M of ADMA Biologics stock for Q1 2022, up 39% quarter-over-quarter.
- 26 funds opened new ADMA Biologics positions in Q1 2022 and 9 closed out, a net change of +17 holders.
- The largest ADMA Biologics buyer in Q1 2022 was Millennium Management, an estimated $4.98M added.
- The largest ADMA Biologics seller in Q1 2022 was Nuveen, an estimated $4.71M sold.
Based on aggregated 13F filings for Q1 2022.